Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

被引:104
作者
Koren, Michael J. [1 ]
Davidson, Michael H. [2 ]
Wilson, Daniel J. [3 ]
Fayyad, Rana S. [3 ]
Zuckerman, Andrea [3 ]
Reed, David P. [3 ]
机构
[1] Jacksonville Ctr Clin Res, Jacksonville, FL 32216 USA
[2] Univ Chicago, Pritzker Sch Med, Cardiol Sect, Chicago, IL 60637 USA
[3] Pfizer Inc, New York, NY USA
关键词
Chronic kidney disease (CKD); coronary heart disease (CHD); statins; kidney function; CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE RESEARCH; CARDIOVASCULAR-DISEASE; RENAL-FUNCTION; PRAVASTATIN; RISK; EPIDEMIOLOGY; OUTCOMES; EVENTS; PEOPLE;
D O I
10.1053/j.ajkd.2008.11.025
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: This post hoc analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study investigates the effect of focused atorvastatin therapy versus usual care on cardiovascular outcomes in patients with coronary heart disease (CHD) with and without chronic kidney disease (CKD). Study Design: Prospective randomized open-label; median follow-up, 54.3 months. Setting & Participants: Managed care or Veterans Affairs facilities; 2,442 patients with CHID with dyslipidemia; mean age, 61.6 years. Intervention: Focused atorvastatin therapy to a low-density lipoprotein cholesterol goal of less than 80 mg/dL or maximum dose of 80 mg/d versus usual care as deemed appropriate by patients' regular physicians. Predictor: Baseline estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease Study equation of less than 60 mL/min/1.73 m(2) (patients with CKD) and 60 mL/min/1.73 m(2) or greater (patients without CKD). Outcomes & Measurements: The primary end point was time to first cardiovascular event. Change from baseline eGFR was assessed in 1,768 patients with follow-up renal data. Results: At baseline, 579 patients (23.7%) had CKD: 31.6% of these patients experienced a primary cardiovascular event during the study versus 23.6% of patients without CKD (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.18 to 1.68; P < 0.001). Compared with usual care, atorvastatin therapy reduced the relative risk of a primary outcome by 28% in patients with CKD (HR, 0.72; 95% CI, 0.54 to 0.97; P = 0.02) and 11 % in patients without CKD (HR, 0.89; 95% CI, 0.74 to 1.07; P = 0.3) (P for treatment by CKD interaction = 0.2). There was no decrease in eGFR in atorvastatin-treated patients during the course of the study. Limitations: Follow-up of atorvastatin patients was restricted to every 6 months; interim data were unavailable for usual-care patients. Conclusions: Patients with CHD and CKD are at increased risk of cardiovascular events. Compared with usual care, focused atorvastatin treatment decreased cardiovascular risk for established patients in real-world settings, with no significant difference in treatment effects observed between patients with and without CKD. Am J Kidney Dis 53:741-750. (C) 2009 by the National Kidney Foundation, Inc.
引用
收藏
页码:741 / 750
页数:10
相关论文
共 28 条
[1]  
[Anonymous], 2002, JAMA, V288, P2998
[2]  
[Anonymous], 2008, Am J Kidney Dis, V51, pS1
[3]   The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J].
Athyros, VG ;
Mikhailidis, DP ;
Papageorgiou, AA ;
Symeonidis, AN ;
Pehlivanidis, AN ;
Bouloukos, VI ;
Elisaf, M .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) :728-734
[4]   A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [J].
Bianchi, S ;
Bigazzi, R ;
Caiazza, A ;
Campese, VM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :565-570
[5]   Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease - A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the councils on high blood pressure research, cardiovascular disease in the young, and epidemiology and prevention; and the quality of care and outcomes research interdisciplinary working group [J].
Brosius, Frank C., III ;
Hostetter, Thomas H. ;
Kelepouris, Ellie ;
Mitsnefes, Mark M. ;
Moe, Sharon M. ;
Moore, Michael A. ;
Pennathur, Subramaniam ;
Smith, Grace L. ;
Wilson, Peter W. F. .
CIRCULATION, 2006, 114 (10) :1083-1087
[6]   The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease [J].
Charytan, D. ;
Kuntz, R. E. .
KIDNEY INTERNATIONAL, 2006, 70 (11) :2021-2030
[7]   Prevalence of chronic kidney disease in the United States [J].
Coresh, Josef ;
Selvin, Elizabeth ;
Stevens, Lesley A. ;
Manzi, Jane ;
Kusek, John W. ;
Eggers, Paul ;
Van Lente, Frederick ;
Levey, Andrew S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (17) :2038-2047
[8]   Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function [J].
Epstein, M ;
Campese, VM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (01) :2-14
[9]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[10]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305